Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06046950

TrEatment Targets in Rheumatoid Arthritis: TETRA-study

There is currently no cure for rheumatoid arthritis (RA), but many treatment options are available. The central aim of RA treatment is lowering disease activity. The proactive treatment strategy called treat to target (T2T) includes measuring disease activity, setting a target and adjusting treatment accordingly until the goal is reached. T2T has proven to be superior to usual care, but there is much debate regarding the most optimal treatment measure and target. The Disease Activity Score with 28-joint counts and c-reactive protein (DAS28CRP) low-disease activity (LDA) target and the more stringent Simplified Disease Activity Index (SDAI) remission target are the best validated targets. Especially the DAS28CRP is the most commonly used in research and practice, whereas the SDAI remission target is most recommended. The European Alliance of Associations for Rheumatology (EULAR) recommends to strive for remission, whereas the American College of Rheumatology (ACR) recommends to strive for LDA. In patients with new and established RA, the (cost)effectiveness of aiming for remission compared to LDA when starting and tapering antirheumatic drugs has not been directly compared. This study therefore aims to directly compare two T2T strategies, aiming at DAS28CRP-LDA and SDAI remission, in patients with established RA.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sint Maartenskliniek

Ubbergen, 6574 NA, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of RA (according to the 2010 or 1987 ACR/ EULAR classification criteria and/or clinical diagnosis)
  • (Starting) use of a DMARD
  • Aged 16 years or older
  • At most low disease activity, operationalised as DAS28-CRP <3.5 (DAS28 CRP 2.9 cut off for low disease activity with measurement error 0.6) or SDAI <19 (SDAI 11 cut off for low disease activity with measurement error of 8). A state of low disease activity is required at inclusion, as for RA patients in moderate or high disease activity there is no equipoise on the best course of action (treatment needs to be escalated).
  • Fluency of Dutch or English, both written and verbally; able to fill in questionnaires
  • Provided informed consent

Exclusion criteria

  • Clinical deep remission, operationalised as SDAI <3.3 or DAS28-CRP <2.4, and an taper attempt in the past 2 years that was discontinued due to occurrence of flare.
  • Fewer than 3 DMARD treatment options left for this patient (severe difficult-to-treat or refractory RA)
  • Current severe comorbidity or other serious life-shortening conditions hampering trial participation
  • Inability to comply with the study protocol or to provide informed consent with regard to intervention control and measuring outcomes

Treatment and study plan

Treatment target DAS28CRP-LDA

Other

Aiming for DAS28CRP-low disease activity

Treatment target SDAI-remission

Other

Aiming for SDAI-remission

Primary outcomes

  1. Achievement of the composite clinical/radiological remission outcome

    Time frame: 18 months follow-up time point

    Achievement of the composite clinical/radiological remission outcome (radiographic progression ≤1 simple erosion narrowing score (SENS), AND, ≤1 swollen joint count, and being in PASS) at 18 months.

Secondary outcomes

  1. The proportion of patients having radiographic progression (defined as > 1 simple erosion narrowing score (SENS) point) in both treatment arms

    Time frame: 18 months follow-up

  2. The number of swollen joints at 18 months follow-up

    Time frame: 18 months follow-up

  3. The proportion of patients achieving 'patient acceptable symptom state' (PASS)

    Time frame: 18 months follow-up

  4. The proportion of patients who reach the predefined target for each treatment arm (DAS28CRP-LDA or SDAI remission)

    Time frame: 18 months follow-up

  5. Percentage of patients that reach LDA or remission, using DAS28CRP- and SDAI-based definitions, in each treatment arm

    Time frame: 18 months follow-up

  6. Daily functioning, measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)

    Time frame: 18 months follow-up

    The Health Assessment Questionnaire-Disability Index (HAQ-DI) will be used to measure the impact of the rheumatoid arthritis on daily functioning. A minimum score of 0 and a maximum score of 60 can be scored. A higher score means a higher impact on daily functioning.

  7. Quality of life (QoL) as defined by the 'EuroQol 5 Dimensions with 5 levels' (EQ5D-5L) questionnaire

    Time frame: 18 months follow-up

    This questionnaire assesses five dimensions of health, including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension can be answered on a 5-point scale, ranging from no problems to extreme problems/unable to. A higher score means a worse outcome.

  8. Incidence density rates of safety ((serious) adverse events, according to CTCAE criteria version 5.0)

    Time frame: 18 months follow-up

  9. Drug use of the patients, consisting of the type and volume of antirheumatic drugs (glucocorticoids, DMARDS, NSAIDs) used over the 18 months period, and at 18 months visit

    Time frame: 18 months follow-up

  10. Costs associated with medical consumption as assessed with the 'Institute for Medical Technology Assessment Medical Consumption Questionnaire' (iMCQ)

    Time frame: 18 months follow-up

  11. Costs associated with loss of productivity as measured bij the 'Institute of Medical Technology Assessment Productivity Cost Questionnaire (iMTA PCQ)

    Time frame: 18 months follow-up

    This is a short generic questionnaire that measures loss of productivity (e.g., both paid and unpaid work) due to illness or recovery.

  12. Proportion of patients of whom the rheumatologist adhered to the local guidelines to treat the patients

    Time frame: 18 months follow-up

    Clinicians are encouraged to adhere to protocol upfront, and adherence is actively monitored, but treatment decisions are ultimately made using shared decision making between patients and physicians. After study completion, adherence will be assessed through a comparison of the target measurements and any changes in treatment regime made by the rheumatologists.

  13. The incidence density rate of flares

    Time frame: 18 months follow-up

Sponsors and collaborators

Lead sponsor

Sint Maartenskliniek

Other

Registry information

Official study title

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study

Acronym: TETRA

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Sep 21, 2023
Registry last updated
Sep 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.